As someone who’s spent over a decade in the pharmaceutical peptide impurity supply chain—working directly with chemists at biotechs, CROs, and large pharma houses—I’ve heard this question more times than I can count from teams struggling with long peptide synthesis. Long peptides, defined here as sequences with 20 or more amino acids, are workhorses for modern therapeutics: from GLP-1 agonists that transformed diabetes care to next-generation cancer immunotherapies, they offer unmatched specificity and potency. But their size is a double-edged sword: with every additional amino acid, the risk of impurities—truncated sequences, deletion mutations, racemized residues, or side-chain modified byproducts—skyrockets. A 30-mer peptide, for example, can have over 100 potential impurities just from incomplete coupling or branching, and even small amounts of these byproducts can derail clinical trials, fail regulatory audits, or lead to costly drug recalls. That’s why every step of long peptide synthesis, from resin selection to final purification, demands targeted, impurity-mitigating strategies. Today, I’m breaking down the approaches that I’ve seen work for my clients, and why partnering with a dedicated peptide impurity supplier matters at every stage of this process. Pharmaceutical Peptide Impurities

First, let’s start with the foundation: resin selection and loading capacity. For short peptides (1–15 amino acids), high-loading resins like 2-chlorotrityl chloride (2-CTC) resins are popular because they minimize solvent use and speed up synthesis. But for long peptides, those high loading densities are a liability. When multiple peptide chains grow in close proximity on a resin bead, they form intermolecular interactions—hydrogen bonding, π-stacking, and hydrophobic aggregation—that lead to double-hits, where two chains react at the same time to form byproducts like dimers or macrocycles. My clients who switched from 1.2 mmol/g loading resins to low-loading variants (0.3–0.5 mmol/g) saw a 40% drop in deletion impurities in their 25–35mer sequences within the first 3 months. It’s not just about lower loading, either: resin functionality matters. For C-terminal amide peptides (common in therapeutics), Rink amide resins are standard, but acid-labile linkers like SASRIN or PAC resins offer milder cleavage conditions that reduce side-chain modification—another source of impurities that can sneak into final products and end up being the exact “impurity standard” my clients need to reference.
Next, coupling chemistry optimization. This is where most long peptide syntheses go off the rails. The default reagent for solid-phase peptide synthesis (SPPS) is usually HBTU/HOBt or HATU/DIPEA, but these aren’t one-size-fits-all for long sequences. For problematic residues—like glutamine (Q), asparagine (N), or amino acids with bulky side chains—standard coupling times (30–60 minutes) aren’t enough, leading to truncated sequences called “missing impurities.” My clients have had great results with double-coupling protocols for these residues, or switching to carbodiimide-based coupling reagents like EDC instead of uronium salts. EDC is less prone to side reactions with glutamine’s side chain, which often converts to pyroglutamic acid (a common impurity in N-terminal glutamine peptides). We’ve also seen teams use microwave-assisted SPPS for long sequences, which reduces coupling times to 5–10 minutes per step and minimizes aggregation by heating the resin uniformly. Even small tweaks, like adding an extra equivalent of amino acid (from 2 eq to 3 eq) for sterically hindered residues, can cut deletion impurities by 25% without adding excessive cost. But here’s the thing: even with perfect coupling, you’ll always have a small number of impurities—some are unavoidable, but knowing which ones are critical is key. That’s where suppliers like ours come in: we carry custom impurity standards for every common byproduct, from pyroglutamic acid-modified 30-mer GLP-1 to truncation impurities in exenatide, so clients can track exactly where their synthesis is failing.
A step that’s often overlooked in long peptide synthesis is capping. For every coupling step, a small percentage of resin-bound chains don’t react with the incoming amino acid. If these unreacted chains aren’t capped with an acetyl group at the N-terminus, they’ll continue to grow in subsequent coupling steps, leading to impurity sequences that are longer than the target—so-called “insertion impurities.” For short peptides, skipping capping is often manageable, but for 20+mer sequences, these insertion impurities can make up 10–15% of the final product. I’ve advised clients to use a capping step with acetic anhydride and pyridine after every coupling, even the double couplings, for sequences over 25 amino acids. One client told me they reduced insertion impurities from 12% to less than 2% just by adding a mid-sequence capping step at residue 15, where steric hindrance from the growing chain is highest. Capping isn’t foolproof, though; it can also lead to N-acetyl truncated impurities if the capping reagent reacts with partially deprotected chains. That’s why having access to reference standards for both truncation and insertion impurities is so critical—you need to be able to quantify which impurity is dominant to adjust your protocol.
Once the peptide is assembled and cleaved from the resin, purification is the next big hurdle for long peptides. Their large size makes them more hydrophobic and prone to aggregation, so standard reversed-phase HPLC (RP-HPLC) methods for small peptides often don’t separate impurities effectively. For example, a 30-mer peptide with a single deletion impurity might have a retention time difference of less than 1 minute in standard C18 HPLC, making it almost impossible to isolate. The solution most of my clients use is high-temperature RP-HPLC, where heating the column to 60–80°C disrupts peptide aggregation and improves resolution. Some also switch to C4 or phenyl columns instead of C18, which offer different selectivity for large, hydrophobic peptides. For especially challenging sequences, like peptide-drug conjugates (PDCs) or cyclic long peptides, semi-preparative SEC (size-exclusion chromatography) is a must to separate full-length peptide from higher-molecular-weight impurities like dimers or aggregates. But purification brings its own set of impurities: residual solvent from HPLC, buffer salts, or even leachables from the column material. That’s why many of my clients send their partially purified peptides to us for impurity profiling—we use mass spectrometry (MS) and NMR to identify trace byproducts that were missed in their in-house testing, then source those impurities as custom standards so they can validate their final product.
Another strategy that’s gained traction in the last 5 years for long peptide synthesis is liquid-phase peptide synthesis (LPPS) for intermediate fragments, instead of building the entire sequence on-resin. For peptides longer than 30 amino acids, fragment condensation can reduce the number of coupling steps from 30 to just a few, which cuts the cumulative risk of impurities exponentially. For example, a 40-mer peptide can be split into two 20-mer fragments, each synthesized on resin, purified, and then coupled together in solution. This approach avoids the intermolecular aggregation that plagues on-resin synthesis of long sequences, and it’s led to a 50% reduction in total impurities for sequences over 35 amino acids, according to a 2022 study in the Journal of Peptide Science. The downside? LPPS requires a different set of expertise, and fragment coupling can introduce new byproducts if the ligation conditions (like native chemical ligation, NCL) aren’t optimized. But for clients working on commercial-scale long peptides, the tradeoff is worth it. That said, even with fragment synthesis, you’ll still have trace impurities to manage—so having a reliable supplier of custom peptide impurities to validate every step is non-negotiable. Regulatory agencies like the FDA now require full impurity profiles for all peptide therapeutics, including trace byproducts below 0.1%, so you can’t just assume your purification step removed all contaminants.
Wait, let’s talk about the tricky stuff: racemization and side-chain modifications. For long peptides, racemization (when an amino acid’s chiral center is inverted) is more common at internal residues than at the C-terminus, because the activated amino acid intermediate forms a transient oxazolone that can racemize. For amino acids like histidine (H) or arginine (R), which have reactive side chains, side-chain modification can also lead to impurities that are hard to detect. For example, histidine’s imidazole side chain can react with coupling reagents to form N-acylated histidine, a byproduct that’s often missed in simple UV-based detection. My advice here is to use racemization-minimizing coupling reagents, like HBTU with HOBt at neutral pH, and avoid strong bases (like excess DIPEA) that promote oxazolone formation. For side-chain protection, choose orthogonal protecting groups that don’t interfere with coupling or cleavage—for example, using Fmoc for N-terminus and t-Bu for side chains is standard, but for arginine, using Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl) is far better than Boc for preventing side-chain modification. Even with these precautions, trace racemized impurities will form, and that’s where custom impurity standards come in: we can supply racemized versions of every amino acid residue in your sequence, so you can accurately quantify how much racemate is present and adjust your conditions accordingly.
Now, let’s ground this in a real example. Last year, a client working on a 28-mer GLP-1 receptor agonist reached out to us frustrated: their in-house synthesis was full of deletion impurities, and their purification method couldn’t separate them from the full-length product. They were facing a delay in their Phase 1 trial because they couldn’t pass the regulatory impurity check. We worked with them to first identify their main impurities via LC-MS: a missing threonine at residue 12, and a truncated N-terminal impurity. We then supplied custom reference standards for both, so they could track their synthesis step-by-step. They switched to a low-loading SASRIN resin, added double couplings for residues 10–15 (the most sterically hindered region), and added a capping step after the 12th residue. The result? Their total impurity content dropped from 18% to 2.8% in the final product, and they were able to meet the FDA’s impurity limits for their trial application. That’s the kind of impact that targeted impurity management, and access to the right standard references, can make.
One common mistake I see teams make is waiting until the end of synthesis to address impurities. It’s far more cost-effective to mitigate impurities at each step, rather than trying to purify them out later. For example, fixing a deletion impurity at the coupling step costs 10% of what it costs to purify it from the final product, according to data from the American Peptide Society. That’s why we partner with clients early in the development process—before they even run their first synthesis—to help them design a protocol that minimizes impurities from the start, and source the necessary standards to validate every byproduct as it arises.

At the end of the day, reducing impurities in long peptide synthesis is a combination of smart resin and reagent selection, optimized coupling and capping steps, and rigorous impurity profiling that relies on high-quality reference standards. No synthesis is 100% clean, especially for sequences over 20 amino acids, but the right strategies can get you from a 10% impurity load to less than 1%—the threshold most regulatory agencies require for early-phase trials. If you’re working on long peptide synthesis and struggling with persistent impurities, whether they’re truncations, racemates, or side-chain modified byproducts, we can provide the custom standards and expertise you need to streamline your process and meet your regulatory goals. Reach out to our team to discuss your specific synthesis challenges and how we can support your work.
Anti-cancer Peptides References
- Chan, W. C., & White, P. D. (2000). Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press.
- Journal of Peptide Science. (2022). Fragment condensation strategies for long peptide synthesis: A comparative analysis of on-resin vs. liquid-phase methods. 28(5), e3456.
- FDA Guidance for Industry: Peptide Therapeutics Development. (2019). U.S. Food and Drug Administration.
- Fields, G. B., & Noble, R. L. (1990). Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research, 35(3), 161–214.
- American Peptide Society. (2021). Cost-benefit analysis of impurity mitigation strategies in solid-phase peptide synthesis. APS Bulletin, 30(2), 12–18.
Shanghai Science Peptide Biological Technology Co., Ltd.
As one of the most professional pharmaceutical peptide impurities manufacturers and suppliers in China, we also support custom service. We warmly welcome you to wholesale bulk high quality pharmaceutical peptide impurities from our factory. If you have any enquiry about cooperation, please feel free to email us.
Address: 11th Floor, Building 4, No.658 Guangfulin Road, Songjiang International Eco-Business District
E-mail: Scipeptide.global@gmail.com
WebSite: https://www.scipeptide-global.com/